KalVista Pharmaceuticals, Inc. (KALV)
| Market Cap | 1.44B +153.6% |
| Revenue (ttm) | 114.48M |
| Net Income | -135.94M |
| EPS | -2.51 |
| Shares Out | 53.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,272,770 |
| Open | 26.98 |
| Previous Close | 26.99 |
| Day's Range | 26.98 - 27.00 |
| 52-Week Range | 9.83 - 27.00 |
| Beta | -0.11 |
| Analysts | Hold |
| Price Target | 28.60 (+5.93%) |
| Earnings Date | Jul 9, 2026 |
About KALV
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmace... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for KALV stock is "Hold." The 12-month stock price target is $28.6, which is an increase of 5.93% from the latest price.
News
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquis...
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children ag...
KalVista Pharmaceuticals Quarterly report: Q1 2026
KalVista Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 14, 2026.
Italian drugmaker Chiesi to buy KalVista for $1.9 billion
Italy's Chiesi has agreed to buy KalVista Pharmaceuticals for about $1.9 billion, the company said on Wednesday, as it looks to grow its rare disease drug portfolio.
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. (“KalVist...
Italian pharma group Chiesi to buy US peer KalVista for $1.9 billion
Italian pharma company Chiesi Group will buy U.S.-listed KalVista Pharmaceuticals in an all-cash deal valued at about $1.9 billion, the two companies said in a joint statement on Wednesday.
KalVista Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
EKTERLY's launch has seen rapid uptake in the US, Germany, and Japan, with strong physician and patient satisfaction and over 20% market penetration. Formulary access is expanding, pediatric and short-term prophylaxis opportunities are advancing, and the company is well-funded to reach profitability.
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham ...
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted five ne...
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new interim results from its KONFIDENT-KID clinical trial evaluating EKTERLY® (se...
KalVista Pharmaceuticals Transcript: Transition period
EKTERLY's U.S. launch drove $49.1M in eight-month revenue, with rapid adoption and strong patient and physician satisfaction. Global expansion is underway, and EKTERLY is now a first-line therapy for adolescents, supporting long-term growth.
KalVista Pharmaceuticals Earnings release: Transition period
KalVista Pharmaceuticals released its earnings on March 25, 2026, summarizing the period's financial results.
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today reported financial results for the eight months ended December 31, 2025, and provided a co...
KalVista Pharmaceuticals Slides: Corporate presentation
KalVista Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that five abstracts, including one late-breaking submission, have been accepted f...
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review t...
KalVista Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026
The conference highlighted the rapid adoption of a new oral on-demand HAE therapy, which is driving earlier and more frequent treatment of attacks, expanding market potential, and shifting patient and prescriber behavior. Growth is strong, with refill rates and sales exceeding expectations.
KalVista Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Ekterly's launch has exceeded expectations, driven by robust clinical data, strong physician and patient satisfaction, and effective support services. Revenue is increasingly driven by refills, with high-burden patients adopting at above-average rates. The company is focused on expanding indications and maintaining its first-mover advantage.
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its sebetralstat clinical trial program presented at the 2026 Ameri...
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following up...
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the newly published International Guideline on the Diagnosis and Management ...
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of three abstracts for presentation at the 2026 American Academy o...
KalVista Pharmaceuticals Slides: Corporate Presentation
KalVista Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on January 9, 2026.
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided its preliminary fourth quarter and full year ended December 31, 2025 unaudited gl...
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted market...